Mallinckrodt Public Profile

34.69
USD 0.55  1.61%
100%
87%

Acquisition by Ian Watkins of 11847 shares of Mallinckrodt Public subject to Rule 16b-3

Mallinckrodt Public Limited Company insider trading alert for grant of share options (right to buy) by Ian Watkins, Sr. VP Chief HR Officer, on August 17, 2018. This event was filed by Mallinckrodt Plc with SEC on 2015-01-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Mallinckrodt Public Summary

Mallinckrodt Public Limited Company (MNK) is traded on New York Stock Exchange in USA. It is located in 3 Lotus Park and employs 3,900 people. The company currently falls under 'Mid-Cap' category with total capitalization of 2.7 B. Mallinckrodt Public Limited Company runs under Healthcare sector within Pharmaceuticals And Biosciences industry. This company has 83.21 M outstanding shares of which 33.5 M shares are now shorted by investors with about 12.75 days to cover shorted positions. ML NIKKEI225 MITT has about 511.9 M in cash with 164.15 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.16.
Check Mallinckrodt Public Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 34.69HorizonTargetOdds Above 34.69
96.04%30 days 34.69 3.93%
Based on normal probability distribution, the odds of Mallinckrodt Public to move above current price in 30 days from now is under 4% (This Mallinckrodt Public Limited Company probability density function shows the probability of Mallinckrodt Public Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares9.6 M180.1 M
Scopia Capital Management LpCommon Shares7.7 M143.2 M
View Mallinckrodt Public Diagnostics

Mallinckrodt Public Risk Profiles

Key Fundamentals

Mallinckrodt Public Against Markets

Current Ratings

Mallinckrodt Public 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
32 
Chance of
Financial Distress (0 to 100%)
23 
Equity ratings for Mallinckrodt Public Limited Company are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company is based in Staines-Upon-Thames, the United Kingdom. Mallinckrodt Public operates under Drug Manufacturers - Specialty Generic classification in USA and traded on BATS Exchange. It employs 00 people. more
NameMallinckrodt Public Limited Company
CEOMark TrudeauView All
Thematic Classification
Currently Active Investing Idea
  Obamacare Repeal
View All
Analyst Consensus
Macroaxis Advice
Bond Rating
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
Business Address3 Lotus Park
ExchangeNew York Stock Exchange
ISINIE00BBGT3753
SectorHealthcare
IndustryPharmaceuticals And Biosciences
BenchmarkDOW
Websitewww.mallinckrodt.com
Phone44 17 8463 6700
CurrencyUSD - US Dollar

Directors

Mallinckrodt Public Corporate Directors
JoAnn Reed Independent Director
Virgil Thompson Independent Director
Diane Gulyas Independent Director
Please see also Stocks Correlation. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.